Dr Robin Portner speaks to ecancer about the data collected from the CONVERT trial regarding the patterns of relapse following thoracic radiotherapy in patients with limited-stage small-cell lung cancer.
Initially, Dr Portner talks about the background and methodology of the study. He then discusses the key findings from the phase III CONVERT trial. He explains that 3 out of 4 patients who relapsed had thoracic progression.
The mapping analysis showed that the majority of thoracic relapses occurred within the high-dose radiotherapy region.This suggests that there is scope for further local treatment intensification.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.